CA3068854A1 - Selective inhibitors of clinically important mutants of the egfr tyrosine kinase - Google Patents

Selective inhibitors of clinically important mutants of the egfr tyrosine kinase Download PDF

Info

Publication number
CA3068854A1
CA3068854A1 CA3068854A CA3068854A CA3068854A1 CA 3068854 A1 CA3068854 A1 CA 3068854A1 CA 3068854 A CA3068854 A CA 3068854A CA 3068854 A CA3068854 A CA 3068854A CA 3068854 A1 CA3068854 A1 CA 3068854A1
Authority
CA
Canada
Prior art keywords
alkyl
alkoxy
independently
compound
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3068854A
Other languages
English (en)
French (fr)
Inventor
Yuntao Song
Alexander James Bridges
Xiaoqi Chen
Original Assignee
CS Pharmatech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CS Pharmatech Ltd filed Critical CS Pharmatech Ltd
Publication of CA3068854A1 publication Critical patent/CA3068854A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3068854A 2017-07-05 2018-07-05 Selective inhibitors of clinically important mutants of the egfr tyrosine kinase Abandoned CA3068854A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762528697P 2017-07-05 2017-07-05
US62/528,697 2017-07-05
PCT/US2018/040904 WO2019010295A1 (en) 2017-07-05 2018-07-05 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE

Publications (1)

Publication Number Publication Date
CA3068854A1 true CA3068854A1 (en) 2019-01-10

Family

ID=64950363

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3068854A Abandoned CA3068854A1 (en) 2017-07-05 2018-07-05 Selective inhibitors of clinically important mutants of the egfr tyrosine kinase

Country Status (7)

Country Link
US (1) US20200131176A1 (enExample)
EP (1) EP3648753A4 (enExample)
JP (1) JP2020526499A (enExample)
KR (1) KR20200028966A (enExample)
CN (1) CN111093645A (enExample)
CA (1) CA3068854A1 (enExample)
WO (1) WO2019010295A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120429A1 (en) 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
ES2963921T3 (es) * 2017-06-13 2024-04-03 Beijing Avlstone Biotechnology Co Ltd Compuestos de aminopirimidina, su método de preparación y uso de los mismos
US20210101881A1 (en) * 2018-02-12 2021-04-08 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Pyrimidine compound, preparation method thereof and medical use thereof
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN111747950B (zh) 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
US12523663B2 (en) 2019-06-04 2026-01-13 Inserm (Institut National De La Santé Et De La Rescherche Médicale) Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021104305A1 (zh) * 2019-11-26 2021-06-03 上海翰森生物医药科技有限公司 含氮多环类衍生物抑制剂、其制备方法和应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021243596A1 (en) * 2020-06-03 2021-12-09 InventisBio Co., Ltd. Aminopyrimidine compounds, preparation methods and uses thereof
KR20220085735A (ko) * 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
KR20240027583A (ko) * 2021-04-30 2024-03-04 수조우 푸허 바이오파마 컴퍼니 리미티드 폐암 치료를 위한 피리미디닐아미노벤젠
CN115667251A (zh) 2021-05-17 2023-01-31 株式会社沃若诺伊生物 杂芳基衍生物化合物、及其用途
CN113651800B (zh) * 2021-09-07 2022-08-19 山东铂源药业股份有限公司 一种甲磺酸奥希替尼的制备方法
CN115650974B (zh) * 2022-08-04 2024-06-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用
WO2024094064A1 (en) * 2022-11-02 2024-05-10 Suzhou Puhe Biopharma Co., Ltd Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
CN120035590A (zh) * 2022-11-03 2025-05-23 株式会社沃若诺伊 Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009262068C1 (en) * 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2016105525A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
WO2017120429A1 (en) * 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CN110818690B (zh) * 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物

Also Published As

Publication number Publication date
WO2019010295A1 (en) 2019-01-10
EP3648753A1 (en) 2020-05-13
JP2020526499A (ja) 2020-08-31
KR20200028966A (ko) 2020-03-17
US20200131176A1 (en) 2020-04-30
CN111093645A (zh) 2020-05-01
EP3648753A4 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
EP3399968B1 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
EP3648753A1 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
JP6254169B2 (ja) ベンズアミドおよびヘテロベンズアミド化合物
JP7118267B2 (ja) がんの処置のためのＨＰＫ１阻害剤としての２，３－ジヒドロ－１Ｈ－ピロロ［３，４－ｃ］ピリジン－１－オン誘導体
CN113214287B (zh) Hpk1抑制剂及其使用方法
KR102483020B1 (ko) Tam 저해제로서의 피롤로트리아진 화합물
CN114394966A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
KR20230003128A (ko) Hpk1 억제제로서의 아잘락탐 화합물
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
HK40057478B (en) Hpk1 inhibitors and methods of using same
HK40017966A (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
HK40084694A (en) Azalactam compounds as hpk1 inhibitors
TW202005967A (zh) Ｅｇｆｒ酪胺酸激酶之臨床上重要的突變體之選擇性抑制劑
HK40004229B (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
HK40004229A (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
HK40002986A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
OA17121A (en) Macrocyclic derivatives for the treatment of proliferative diseases

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240105